MX343328B - Analisis para la deteccion de farmacos anti-tnf y anticuerpos. - Google Patents
Analisis para la deteccion de farmacos anti-tnf y anticuerpos.Info
- Publication number
- MX343328B MX343328B MX2014002586A MX2014002586A MX343328B MX 343328 B MX343328 B MX 343328B MX 2014002586 A MX2014002586 A MX 2014002586A MX 2014002586 A MX2014002586 A MX 2014002586A MX 343328 B MX343328 B MX 343328B
- Authority
- MX
- Mexico
- Prior art keywords
- autoantibodies
- assays
- detection
- tnf drugs
- level
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 229940079593 drug Drugs 0.000 title abstract 4
- 238000003556 assay Methods 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 abstract 1
- 241000989913 Gunnera petaloidea Species 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rehabilitation Therapy (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25504809P | 2009-10-26 | 2009-10-26 | |
| US26287709P | 2009-11-19 | 2009-11-19 | |
| US32463510P | 2010-04-15 | 2010-04-15 | |
| US34556710P | 2010-05-17 | 2010-05-17 | |
| US35126910P | 2010-06-03 | 2010-06-03 | |
| US38967210P | 2010-10-04 | 2010-10-04 | |
| US39358110P | 2010-10-15 | 2010-10-15 | |
| PCT/US2010/054125 WO2011056590A1 (en) | 2009-10-26 | 2010-10-26 | Assays for the detection of anti-tnf drugs and autoantibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX343328B true MX343328B (es) | 2016-11-01 |
Family
ID=43618083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002586A MX343328B (es) | 2009-10-26 | 2010-10-26 | Analisis para la deteccion de farmacos anti-tnf y anticuerpos. |
| MX2012004877A MX2012004877A (es) | 2009-10-26 | 2010-10-26 | Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004877A MX2012004877A (es) | 2009-10-26 | 2010-10-26 | Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos. |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US8574855B2 (de) |
| EP (1) | EP2494352B1 (de) |
| JP (3) | JP5697677B2 (de) |
| KR (2) | KR101761541B1 (de) |
| CN (2) | CN104634955B (de) |
| AU (4) | AU2010315547C1 (de) |
| BR (1) | BR112012009855A2 (de) |
| CA (2) | CA2778454C (de) |
| ES (1) | ES2796530T3 (de) |
| IL (2) | IL219315B (de) |
| MX (2) | MX343328B (de) |
| NZ (3) | NZ706187A (de) |
| RU (2) | RU2571489C2 (de) |
| WO (1) | WO2011056590A1 (de) |
| ZA (2) | ZA201203717B (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1561756T3 (en) | 2002-09-11 | 2016-02-15 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR CLEANING PROTEIN. |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ706187A (en) | 2009-10-26 | 2016-09-30 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
| CN103299190B (zh) | 2010-10-18 | 2017-02-15 | 雀巢产品技术援助有限公司 | 确定抗药物抗体同种型的方法 |
| EP2676137B1 (de) * | 2011-02-17 | 2014-12-31 | Nestec S.A. | Tests für den nachweis von autoantikörpern gegen anti-tnf-arzneimittel |
| RU2013154566A (ru) | 2011-05-10 | 2015-06-20 | Нестек С.А. | Способы анализа профиля активности болезни с целью проведения индивидуального лечения |
| WO2013006810A1 (en) * | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| US20140017174A1 (en) * | 2011-11-30 | 2014-01-16 | Raja Atreya | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
| WO2013132000A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes |
| US20130295685A1 (en) * | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
| US10132736B2 (en) | 2012-05-24 | 2018-11-20 | Abbvie Inc. | Methods for inspection of protein particles in a liquid beneficial agent |
| WO2014046474A2 (ko) * | 2012-09-21 | 2014-03-27 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
| KR101501375B1 (ko) | 2012-09-21 | 2015-03-10 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
| EP3217179B9 (de) | 2012-10-05 | 2020-06-10 | Prometheus Biosciences, Inc. | Verfahren zur voraussage und überwachung von mukosaler wundheilung |
| BR112015012482A2 (pt) * | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
| EP2954329A1 (de) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Verfahren zur auswahl einer kombinationstherapie für darmkrebspatienten |
| WO2014184768A1 (en) * | 2013-05-16 | 2014-11-20 | University Of Pretoria | A method of diagnosing tuberculosis |
| CA2932571A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Methods for predicting post-operative recurrence of crohn's disease |
| CA2932569A1 (en) | 2013-12-03 | 2015-06-11 | Societe Des Produits Nestle S.A. | Signaling pathways in tissues from inflammatory bowel disease patients |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
| MX2017004816A (es) | 2014-10-20 | 2017-08-02 | Nestec Sa | Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa. |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| MX2017006959A (es) | 2014-12-02 | 2017-08-10 | Nestec Sa | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. |
| WO2016088104A2 (en) * | 2014-12-05 | 2016-06-09 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
| WO2016110595A1 (en) * | 2015-01-09 | 2016-07-14 | Atonomics A/S | A UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFα INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES |
| WO2016135707A1 (en) | 2015-02-27 | 2016-09-01 | Nestec S.A. | Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders |
| EP3165928B1 (de) | 2015-11-06 | 2019-01-09 | Promise Advanced Proteomics | Verfahren zur quantifizierung von anti-tnf-antikörpern |
| ES2815224T3 (es) | 2015-11-06 | 2021-03-29 | Promise Proteomics | Un método para cuantificar anticuerpos terapéuticos |
| WO2017201142A1 (en) * | 2016-05-17 | 2017-11-23 | Memorial Sloan Kettering Cancer Center | Treatment of lung adenocarcinoma |
| JP2019522199A (ja) | 2016-07-08 | 2019-08-08 | アトノミックス アクティーゼルスカブ | 試料中の治療用モノクローナル抗体及びそれらの対応する抗薬物抗体の量を確定するためのユニバーサルアッセイ |
| CA3078779A1 (en) | 2017-10-10 | 2019-04-18 | Prometheus Biosciences, Inc. | Methods for monitoring vedolizumab treatment |
| EP3514541A1 (de) * | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors |
| AU2019256647B2 (en) * | 2018-04-20 | 2024-08-15 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-IL12/IL23 antibody compositions |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| AU2020231509A1 (en) * | 2019-03-04 | 2021-08-19 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| KR102562006B1 (ko) | 2020-11-09 | 2023-08-02 | 바디텍메드(주) | 항tnf-알파 약물 모니터링을 위한 신속 검출 키트 |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
| US4459359A (en) | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
| FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| EP0440044A1 (de) | 1990-01-31 | 1991-08-07 | Abbott Laboratories | Verfahren zur Vermeidung humaner Anti-Maus-Antikörper-Störungen in den in vitro diagnostischen Bestimmungsverfahren |
| US5094740A (en) | 1990-02-16 | 1992-03-10 | Glycomed, Inc. | Two-dimensional electrophoretic separation of carbohydrates |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5582998A (en) | 1991-06-19 | 1996-12-10 | Boehringer Ingelheim International Gmbh | Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor |
| JPH0566222A (ja) | 1991-09-09 | 1993-03-19 | Tosoh Corp | 物質の分析方法 |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| DE69426223T2 (de) | 1993-09-07 | 2001-05-23 | Wako Pure Chemical Industries, Ltd. | Verfahren und Reagenz zur Messung der Komplementaktivität |
| JPH07110331A (ja) * | 1993-09-07 | 1995-04-25 | Wako Pure Chem Ind Ltd | ヒト補体価測定方法及びヒト補体価測定用試薬組成物 |
| JPH07140144A (ja) | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法 |
| EP1298144A3 (de) | 1994-12-28 | 2006-05-31 | University of Kentucky Research Foundation | Monoklonaler anti-idiotypischer Antikörper aus der Maus 3H1 |
| CN100429232C (zh) * | 1996-02-09 | 2008-10-29 | 艾博特生物技术有限公司 | 体外抑制人TNFα活性的方法 |
| EP0882984B1 (de) | 1996-08-12 | 2010-10-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | BEHäLTER UND KITS ZUR BESTIMMUNG VON ZELLFUNKTIONEN UND VERFAHREN ZU DEREN BESTIMMUNG |
| JP3718435B2 (ja) * | 1996-08-12 | 2005-11-24 | 積水化学工業株式会社 | 細胞機能測定用容器及び細胞機能測定方法 |
| US6391622B1 (en) | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| WO2000026394A1 (en) * | 1998-10-31 | 2000-05-11 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
| DE19858777B4 (de) * | 1998-12-18 | 2006-07-27 | Delta Biotechnology Ltd. | Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen |
| US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| AU776395B2 (en) * | 1999-12-06 | 2004-09-09 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Aminobenzophenones as inhibitors of IL-1beta and TNF-alpha |
| EP1238077A1 (de) | 1999-12-16 | 2002-09-11 | Amgen Inc., | Tnfr/opg-ähnliches protein und dessen verwendungen |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| EP1370867B1 (de) | 2001-03-02 | 2010-08-04 | Activx Biosciences, Inc. | Plattform für protein-profiling |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030040027A1 (en) | 2001-08-16 | 2003-02-27 | Gerd Ritter | Method for determining protein component in a biological sample |
| DE60236536D1 (de) | 2001-11-12 | 2010-07-08 | Merck Patent Gmbh | Modifizierter anti-tnf antikörper |
| AU2002347152A1 (en) | 2001-12-05 | 2003-06-17 | Cangene Corporation | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| JP2006509724A (ja) | 2002-08-01 | 2006-03-23 | ワイス | 炎症及びアポトーシスに関係する方法及び試薬 |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005094200A2 (en) | 2003-06-20 | 2005-10-13 | University Of Florida | Biomarkers for differentiating between type 2 and type 2 diabetes |
| BRPI0413197A (pt) * | 2003-08-01 | 2006-10-03 | Amgen Inc | cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept |
| JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスｙ抗イディオタイプ抗体およびその使用 |
| EP1519194A1 (de) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung |
| US20090275496A1 (en) | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| EP1769244A4 (de) | 2004-06-30 | 2008-05-14 | Dow Kenneth Centocor Inc | Nachweis oder messung von antigenprotein-antikörpern in biologischen geweben oder proben |
| US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
| US7601335B2 (en) | 2005-05-20 | 2009-10-13 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
| CA2615846A1 (en) | 2005-07-21 | 2007-01-25 | Genmab A/S | Potency assays for antibody drug substance binding to an fc receptor |
| EP1937307A4 (de) | 2005-09-14 | 2009-05-13 | Hutchinson Fred Cancer Res | Spezifische entfernung von aktivierten immunzellen |
| US7542502B2 (en) | 2005-09-27 | 2009-06-02 | Cymer, Inc. | Thermal-expansion tolerant, preionizer electrode for a gas discharge laser |
| AU2006311475A1 (en) * | 2005-11-08 | 2007-05-18 | Medarex, Inc. | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| JP2007147367A (ja) | 2005-11-25 | 2007-06-14 | Sekisui Chem Co Ltd | サイトカイン産生能の測定方法 |
| DE102005057920A1 (de) | 2005-12-02 | 2007-06-28 | Strohner, Pavel, Dr. | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben |
| WO2008008349A2 (en) | 2006-07-11 | 2008-01-17 | Drexel University | Methods of quantitatively assessing inflammation with biosensing nanoparticles |
| US20080286774A1 (en) | 2007-05-16 | 2008-11-20 | The Regents Of The University Of California | Real-time individualized therapy evaluation |
| US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| WO2009042114A2 (en) * | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| AU2008348252A1 (en) * | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| EP2263085A4 (de) | 2008-03-05 | 2011-07-06 | Singulex Inc | Verfahren und zusammensetzungen zur hochempfindlichen erkennung von molekülen |
| NZ706187A (en) | 2009-10-26 | 2016-09-30 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
| CN103299190B (zh) | 2010-10-18 | 2017-02-15 | 雀巢产品技术援助有限公司 | 确定抗药物抗体同种型的方法 |
| EP2676137B1 (de) | 2011-02-17 | 2014-12-31 | Nestec S.A. | Tests für den nachweis von autoantikörpern gegen anti-tnf-arzneimittel |
| US20130266963A1 (en) | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| WO2013006810A1 (en) | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| US20140051184A1 (en) | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
| US20130295685A1 (en) | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
| BR112015012482A2 (pt) | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
| WO2016088104A2 (en) | 2014-12-05 | 2016-06-09 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
-
2010
- 2010-10-26 NZ NZ706187A patent/NZ706187A/en not_active IP Right Cessation
- 2010-10-26 CN CN201510067719.1A patent/CN104634955B/zh not_active Expired - Fee Related
- 2010-10-26 CA CA2778454A patent/CA2778454C/en active Active
- 2010-10-26 KR KR1020127013748A patent/KR101761541B1/ko not_active Expired - Fee Related
- 2010-10-26 MX MX2014002586A patent/MX343328B/es unknown
- 2010-10-26 KR KR1020177020281A patent/KR101881714B1/ko not_active Expired - Fee Related
- 2010-10-26 CN CN201080060442.5A patent/CN102695955B/zh not_active Expired - Fee Related
- 2010-10-26 RU RU2012121710/15A patent/RU2571489C2/ru not_active IP Right Cessation
- 2010-10-26 MX MX2012004877A patent/MX2012004877A/es active IP Right Grant
- 2010-10-26 RU RU2015148676A patent/RU2015148676A/ru not_active Application Discontinuation
- 2010-10-26 NZ NZ621655A patent/NZ621655A/en not_active IP Right Cessation
- 2010-10-26 WO PCT/US2010/054125 patent/WO2011056590A1/en not_active Ceased
- 2010-10-26 ES ES10778763T patent/ES2796530T3/es active Active
- 2010-10-26 EP EP10778763.2A patent/EP2494352B1/de active Active
- 2010-10-26 AU AU2010315547A patent/AU2010315547C1/en not_active Ceased
- 2010-10-26 NZ NZ599456A patent/NZ599456A/en not_active IP Right Cessation
- 2010-10-26 JP JP2012536962A patent/JP5697677B2/ja not_active Expired - Fee Related
- 2010-10-26 BR BR112012009855A patent/BR112012009855A2/pt not_active Application Discontinuation
- 2010-10-26 CA CA3108458A patent/CA3108458A1/en active Pending
-
2012
- 2012-04-06 US US13/441,727 patent/US8574855B2/en active Active
- 2012-04-19 IL IL219315A patent/IL219315B/en not_active IP Right Cessation
- 2012-05-22 ZA ZA2012/03717A patent/ZA201203717B/en unknown
-
2013
- 2013-10-04 US US14/046,863 patent/US8865417B2/en active Active
-
2014
- 2014-07-21 US US14/336,955 patent/US9506920B2/en active Active
-
2015
- 2015-02-10 JP JP2015024359A patent/JP5878253B2/ja not_active Expired - Fee Related
- 2015-05-28 AU AU2015202899A patent/AU2015202899B2/en not_active Ceased
- 2015-06-23 ZA ZA201504548A patent/ZA201504548B/en unknown
-
2016
- 2016-01-26 JP JP2016012688A patent/JP6082831B2/ja not_active Expired - Fee Related
- 2016-10-19 US US15/297,878 patent/US10386366B2/en active Active
-
2017
- 2017-08-14 AU AU2017213584A patent/AU2017213584B2/en not_active Ceased
-
2018
- 2018-01-04 IL IL256728A patent/IL256728A/en unknown
-
2019
- 2019-07-02 US US16/460,597 patent/US20200018751A1/en not_active Abandoned
- 2019-07-12 AU AU2019205009A patent/AU2019205009A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX343328B (es) | Analisis para la deteccion de farmacos anti-tnf y anticuerpos. | |
| MX343327B (es) | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. | |
| ATE472110T1 (de) | Sensoreinrichtung und verfahren zur erfassung von magnetischen teilchen | |
| EP3264090A3 (de) | Verfahren zur erkennung von nukleosomaddukten | |
| CO6680668A2 (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
| FR2996673B1 (fr) | Capteur capacitif pour la detection de presence d'un objet et/ou d'un individu. | |
| FR2969916B1 (fr) | Systeme et procede pour detecter la sensibilite d'une personne a une ou plusieurs substances possiblement allergisantes | |
| EP2596132A4 (de) | Verfahren zur erkennung von anzeichen für krankheiten oder leiden in körperflüssigkeiten | |
| MX2013013986A (es) | Deteccion rapida de actividad metabolica. | |
| WO2011144948A3 (en) | Detecting descented material | |
| WO2013009703A8 (en) | Antibodies, kit and method for detecting amyloid beta oligomers | |
| MX2015006852A (es) | Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica. | |
| EP2573192A4 (de) | Verfahren und kit zur diagnose aim-vermittelter erkrankungen | |
| FR2953292B1 (fr) | Capteur d'hydrogene et procede de detection d'une concentration en hydrogene. | |
| MX2015000684A (es) | Metodo para detectar cancer. | |
| FR2963682B1 (fr) | Procede de detection d'objet au moyen d'un capteur de proximite | |
| MX2016005313A (es) | Deteccion de la actividad de corte de una enzima. | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| EP4386381A3 (de) | Sensor zur detektion von gas und verfahren zur detektion von gas | |
| BRPI1009573A2 (pt) | método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente. | |
| WO2012071344A3 (en) | Nucleotide-based probes and methods for the detection and quantification of macromolecules and other analytes | |
| GB2470757B (en) | Non invasive gas analysis | |
| FR2949155B1 (fr) | Procede de mesure ou de detection de l'encrassement d'un reacteur | |
| WO2013101276A3 (en) | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway | |
| MX2014011045A (es) | Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. |